Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Vsevolod V Gurevich
 -- 2126 2022-07-15 23:31:15 |
2 format correct
Vivi Li
 + 39 word(s) 2165 2022-07-18 03:46:31 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Gurevich, V.V.;  Gurevich, E.V. Monomers and Oligomers of Arrestin Proteins. Encyclopedia. Available online: https://encyclopedia.pub/entry/25193 (accessed on 03 July 2024).
Gurevich VV,  Gurevich EV. Monomers and Oligomers of Arrestin Proteins. Encyclopedia. Available at: https://encyclopedia.pub/entry/25193. Accessed July 03, 2024.
Gurevich, Vsevolod V., Eugenia V. Gurevich. "Monomers and Oligomers of Arrestin Proteins" Encyclopedia, https://encyclopedia.pub/entry/25193 (accessed July 03, 2024).
Gurevich, V.V., & Gurevich, E.V. (2022, July 15). Monomers and Oligomers of Arrestin Proteins. In Encyclopedia. https://encyclopedia.pub/entry/25193
Gurevich, Vsevolod V. and Eugenia V. Gurevich. "Monomers and Oligomers of Arrestin Proteins." Encyclopedia. Web. 15 July, 2022.
Monomers and Oligomers of Arrestin Proteins
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms23137253

Three out of four subtypes of arrestin proteins expressed in mammals self-associate, each forming oligomers of a distinct kind. Monomers and oligomers have different subcellular localization and distinct biological functions. Visual arrestin (a.k.a. S-antigen, 48 kDa protein, and rod arrestin; systematic name arrestin-1) is expressed in rod and cone photoreceptor cells in the retina, whereas arrestin-4 is expressed exclusively in cones at a much lower level than arrestin-1.

arrestin oligomerization signaling conformation

1. Arrestins: A Small Family with Many Functions

Mammals express only four arrestin subtypes [1]. Visual arrestin (a.k.a. S-antigen, 48 kDa protein, and rod arrestin; systematic name arrestin-1) is expressed in rod and cone photoreceptor cells in the retina, whereas arrestin-4 is expressed exclusively in cones at a much lower level than arrestin-1 [2]. Both quench G protein-mediated signaling of photopigments [2][3]. The first family member discovered, arrestin-1 [4], ensures rapid recovery in rods [5][6][7] by shutting down light-induced signaling of the prototypical G protein-coupled receptor (GPCR) rhodopsin [8][9][10] with sub-second kinetics in mammals [11]. The first non-visual arrestin subtype was also discovered as a protein that turns off G protein-mediated receptor signaling [12]. It was termed β-arrestin (systematic name, arrestin-2) because it preferred β2-adrenergic receptor over rhodopsin, in contrast to arrestin-1 with the opposite preference [12][13]. The second cloned non-visual arrestin subtype also quenched G protein-mediated signaling and preferred β2-adrenergic receptor over rhodopsin. Therefore, it was termed β-arrestin2, with the retroactive renaming of the first one, β-arrestin1 [14]. The same protein was cloned from human thyroid and named hTHY-ARRX [15]. As by that time it became clear that non-visual arrestins bind not only β2-adrenergic receptor, but many other GPCRs, systematic nomenclature was proposed, where the number after “arrestin” indicated the order of cloning without implying anything else, so that β-arrestin2 was termed arrestin-3 [16]. The cone photoreceptor-specific arrestin was cloned later and termed X-arrestin in one study [17] and cone arrestin in another [18]. As it was cloned last, its systematic name is arrestin-4. Below, researchers use systematic names of arrestin proteins.
In addition to precluding GPCR coupling to cognate G proteins, both non-visual subtypes were shown to be involved in various branches of cellular signaling (reviewed in [19][20]), interacting with >100 partners each [21], i.e., demonstrating a remarkable versatility for an average-sized ~45 kDa protein (reviewed in [22]). The overall structures of arrestin-1 [23][24][25], arrestin-2 [26][27], arrestin-3 [28], and arrestin-4 [29] monomers are remarkably similar. However, all arrestin subtypes, with the sole exception of cone-specific arrestin-4, oligomerize [30], and the oligomers they form are strikingly different.

2. Arrestin-1

Arrestin-1 crystallized in two labs under different conditions, forming virtually identical tetramers [23][24] (Figure 1A,B), which suggested that it might oligomerize in vivo. Indeed, it was found to exist in a monomer–dimer–tetramer equilibrium in solution [31]. In the crystal tetramer, many elements of arrestin-1 known at the time to be involved in receptor binding were shielded by sister protomers. Thus, an idea that oligomers are storage forms was proposed [31]. Subsequent studies using pulse EPR technique double electron–electron resonance (DEER) showed that the shape of the tetramer of arrestin-1 in solution is very different from that of the crystal tetramer: the four protomers form a closed diamond [32] (Figure 2). This model of the solution tetramer was confirmed by successful disruption of arrestin-1 self-association with mutations targeting predicted protomer–protomer interaction sites [33][34]. In the solution tetramer and both possible dimers forming it, the receptor-binding elements of the monomers were also shielded by sister protomers. Moreover, it was directly demonstrated that only monomeric arrestin-1 binds rhodopsin [35], supporting the idea that if rhodopsin binding is its only function, oligomers must serve some other purpose. The study using multi-angle light scattering (MALS) confirmed that bovine arrestin-1 oligomerizes in solution, forming dimers that associate into tetramers [30]. Measurements of dimerization and tetramerization constants suggested that in case of bovine arrestin-1, tetramer formation is a cooperative process [30]. Monomer–dimer–tetramer equilibrium in solution was found to be a common feature of bovine, mouse, and human arrestin-1, although dimerization and tetramerization constants in these species are quite different [33]. Rods express enormous amounts of arrestin-1 (intracellular concentrations were estimated at ~2 mM), which is the second most abundant protein in these photoreceptors after rhodopsin [36][37][38]. In fact, the level of arrestin-1 in rods is 4–5 orders of magnitude greater than usual levels of the non-visual subtypes in “normal” cells, including neurons, which is in most cases ~20–200 nM [39][40]. Comparison of oligomerization constants with calculated concentrations of mouse arrestin-1 in photoreceptors suggested that the bulk of arrestin-1 in cells must be oligomeric. Apparently, the majority of arrestin-1 molecules in rods exist as dimers or tetramers, depending on the species [33]. The most parsimonious explanation of this is that oligomers are storage forms for arrestin-1 when it is free and not bound to rhodopsin.
Figure 1. Crystal tetramer of bovine arrestin-1. (A), side view. (B), top view. PDB ID 1CF1 [24]. In each protomer arrestin-1 elements are colored, as follows: N-domain (residues 1–178), blue; inter-domain hinge (residues 179–190), yellow; C-domain (residues 191–356), green; C-tail (from residue 357; the gap reflects that part of the C-tail are invisible in crystal), red. Images were created in DS ViewerPro 6.0 (Dassault Systèmes, San Diego, CA, USA).
Ijms 23 07253 g002 550
Figure 2. Solution tetramer of bovine arrestin-1. The image is based on the published model [32]. The color code is the same as in Figure 1. Image was created in DS ViewerPro 6.0 (Dassault Systèmes, San Diego, CA, USA).
However, it has not been clear why arrestin-1 needs to have these storage forms, i.e., why it could not be stored as a monomer. The first indication that the monomer might be harmful for rods came from in vivo experiments in mice using “enhanced” arrestin-1 mutant that binds unphosphorylated light-activated rhodopsin much better than wild type (WT) protein. Arrestin-1 binds with high affinity to active phosphorylated rhodopsin, shutting off the rhodopsin response to light and initiating a rapid recovery process (reviewed in [41]). Defects in rhodopsin phosphorylation or a lack of functional arrestin-1 in humans result in the loss of the rod function and night blindness [42][43]. Mice lacking rhodopsin kinase, which phosphorylates rhodopsin in rods upon light activation, or mice lacking arrestin-1 are effectively blind under normal light conditions, because rhodopsin signaling is not stopped, and therefore rods have no chance to recover [3][44]. Researchers attempted to compensate for the lack of rhodopsin phosphorylation in rhodopsin kinase knockout mice by expressing a phosphorylation-independent arrestin-1 mutant in rods, which was expected to bind light-activated unphosphorylated rhodopsin and facilitate recovery. This compensational approach worked in principle, significantly reducing the recovery time [45][46]. However, the enhanced mutant used, which also happened to be partially oligomerization-deficient [34], when expressed either on the rhodopsin kinase or arrestin-1 knockout background, caused rapid degeneration of photoreceptor cells, the severity of which increased with its expression level [47]. Interestingly, consistent with the improved rhodopsin shutoff kinetics, the retinal degeneration caused by this mutant was light-independent. Researchers have shown earlier that even very high supra-physiological levels of normally oligomerizing WT arrestin-1 were harmless for rods [36]. Furthermore, WT arrestin-1 co-expressed with the mutant dose-dependently protected, albeit partially, the rods from the mutant-induced degeneration [47]. These data suggested that the retinal degeneration caused by the arrestin-1 mutant might be due to an elevated concentration of a cytotoxic monomer. The protection afforded by WT arrestin-1 could then be easily explained by the known ability of oligomerization-competent WT arrestin-1 to draw partially oligomerization-deficient mutants into oligomers [47].
The oligomerization defect was not the only functional characteristic of the mutant different from that of WT arrestin-1. Another feature of the mutant, an enhanced interaction with clathrin adaptor AP2, was earlier shown to be harmful for the photoreceptor cells [48]. Thus, testing whether defective self-association per se is the culprit, required the replacement in vivo of WT arrestin-1 with an oligomerization-deficient mutant that otherwise has WT-like functional characteristics. An arrestin-1 with mutations that selectively impair oligomerization but do not affect rhodopsin binding was constructed and transgenically expressed in arrestin-1 knockout mice, replacing the WT protein [49]. A thorough analysis of these animals showed that non-oligomerizing protein normally quenches rhodopsin signaling [49], consistent with previous finding that arrestin-1 binds rhodopsin as a monomer [35]. However, arrestin-1 mutant with defective oligomerization and WT-like rhodopsin-binding characteristics caused progressive retinal degeneration, which was faster in lines with higher expression and did not depend on illumination at all, i.e., it proceeded at the same pace in dark-reared animals [49]. These data support the earlier conclusion that arrestin-1 monomer at high concentration is toxic for rod photoreceptors. Since rods do express arrestin-1 at very high levels [36][37][38], oligomerization might be required to prevent cytotoxicity. Calculations based on absolute arrestin-1 concentrations in mouse rods [36] and dimerization and tetramerization constants of mouse arrestin-1 [33] suggest that monomer concentration in WT rods is ~ 95 μM [49]. The data with mice expressing oligomerization-deficient arrestin-1 show that rods tolerate up to 500 μM of monomer, but higher concentrations are harmful [49]. Thus, available data suggest that monomeric and oligomeric forms of arrestin-1 are functionally different. The molecular mechanism whereby monomeric arrestin-1 exerts its cytotoxic effect still needs to be elucidated. It is also unknown whether arrestin-1 oligomers (dimers or tetramers) have specific functions in rods that the monomer cannot serve. These functions might be species-specific, as the predominant form of bovine and mouse arrestin-1 in the dark is likely a tetramer, whereas in humans dimers predominate [33].
In the dark, WT arrestin-1 is mostly localized to the rod inner segments and partially to the cell bodies and synaptic terminals, but in the light the bulk of it translocates to the rhodopsin-containing outer segments (OS) [50]. The arrestin-1 translocation has been shown to be a passive diffusion-driven process, with arrestin-1 moving along the gradients produced by its binding to the preferred partners in the light and dark [50][51]. When rhodopsin is activated by photons of light, it becomes rapidly phosphorylated by rhodopsin kinase. Then arrestin-1 monomer binds with high affinity to light-activated phosphorylated rhodopsin [35]. This shifts the monomer–dimer–tetramer equilibrium towards the monomer. As free arrestin-1 in the OS is depleted by its binding to rhodopsin, this process creates a concentration gradient driving the diffusion of arrestin-1 to the OS. In the dark, when rhodopsin is inactive, arrestin-1 is kept in other compartments via its binding to non-rhodopsin partners, most likely to microtubules particularly abundant in the inner segments [52]. Indeed, in the absence of higher affinity partners, such as light activated rhodopsin, arrestin-1 distribution resembles that of microtubules, and this is observed in the case of both WT arrestin-1 [50] and its oligomerization-deficient mutant [49].
Recently, an interesting model was proposed to explain the localization of arrestin-1 in the dark away from its “place of employment”, i.e., OS: oligomers were hypothesized to be too big to fit in the spaces between the rhodopsin-containing discs [53]. Indeed, the rod OS, where rhodopsin and the rest of the signal transduction machinery is localized, are filled with closely packed membranous discs housing rhodopsin with fairly narrow cytoplasmic spaces between them. This model predicts that in the dark, oligomerization-deficient arrestin-1 would be distributed in rod photoreceptors more evenly, with a significantly greater proportion localized to the OS. However, the subcellular distribution of an oligomerization-deficient mutant, which predominantly exists as a monomer, in both dark and light faithfully recapitulated that of the WT arrestin-1 [49], burying this beautifully simple model. The binding of arrestin-1 to the microtubules as a factor holding it in the dark in the inner segments and cell bodies remains the most likely explanation, particularly since both monomeric and oligomeric arrestin-1 bind microtubules well [35][54]. It is worth noting that while arrestin-1 has a microtubule-binding site overlapping with the rhodopsin footprint [54], which is shielded in the oligomeric forms [32], relatively low-affinity binding to microtubules appears to also be supported by the surfaces exposed in oligomers, as microtubule interaction, unlike rhodopsin binding, does not promote the dissociation of arrestin-1 oligomers into monomers [35].

3. Arrestin-2

Arrestin-2 crystallized as a dimer [26], which suggested that it also might oligomerize. Self-association of arrestin-2 in cells was described in 2005 [55]. Structural studies and extensive mutagenesis showed that arrestin-2 oligomerization involves two binding sites for an abundant cytosolic metabolite inositol-hexakisphosphate (IP6), one on the N- and the other on the C-domain, both on the concave (receptor-binding) side [56]. Importantly, the structure of arrestin-2 in crystals soaked with IP6 revealed long chains of arrestin-2, where the protomers interacted in an N-to-C-domain fashion, glued together by IP6 molecules between concave sides of the two domains of neighboring protomers [56] (Figure 3). This arrangement suggested that an oligomer is unlikely to bind GPCRs, as receptor-binding surfaces of arrestin-2 in it are shielded by neighboring protomers.
Ijms 23 07253 g003 550
Figure 3. Crystal oligomer of bovine arrestin-2 in the presence of IP6. Based on PDB ID 1ZSH [56]. Arrestin-2 oligomer in the presence of IP6 appears to form the same “infinite” chains in solution [57], with each protomer in basal conformation, crystal structure of which was solved earlier (PDB ID 1G4M [26] and 1ZSH [27]). Arrestin-2 in crystal forms “infinite” chains with no apparent limit. Three molecules making IP6-mediated N-to-C contacts are shown. In each protomer arrestin-2 elements are colored, as follows: N-domain (residues 1–172), blue; inter-domain hinge (residues 173–184), yellow; C-domain (residues 185–352), green; C-tail (from residue 353), red (note the gap, as part of this element was not resolved in the crystal structure). Image was created in DS ViewerPro 6.0 (Dassault Systèmes, San Diego, CA, USA).

References

  1. Indrischek, H.; Prohaska, S.J.; Gurevich, V.V.; Gurevich, E.V.; Stadler, P.F. Uncovering missing pieces: Duplication and deletion history of arrestins in deuterostomes. BMC Evol. Biol. 2017, 17, 163.
  2. Nikonov, S.S.; Brown, B.M.; Davis, J.A.; Zuniga, F.I.; Bragin, A.; Pugh, E.N., Jr.; Craft, C.M. Mouse cones require an arrestin for normal inactivation of phototransduction. Neuron 2008, 59, 462–474.
  3. Xu, J.; Dodd, R.L.; Makino, C.L.; Simon, M.I.; Baylor, D.A.; Chen, J. Prolonged photoresponses in transgenic mouse rods lacking arrestin. Nature 1997, 389, 505–509.
  4. Kuhn, H. Light-regulated binding of rhodopsin kinase and other proteins to cattle photoreceptor membranes. Biochemistry 1978, 17, 4389–4395.
  5. Mendez, A.; Burns, M.E.; Roca, A.; Lem, J.; Wu, L.W.; Simon, M.I.; Baylor, D.A.; Chen, J. Rapid and reproducible deactivation of rhodopsin requires multiple phosphorylation sites. Neuron 2000, 28, 153–164.
  6. Azevedo, A.W.; Doan, T.; Moaven, H.; Sokal, I.; Baameur, F.; Vishnivetskiy, S.A.; Homan, K.T.; Tesmer, J.J.; Gurevich, V.V.; Chen, J.; et al. C-terminal threonines and serines play distinct roles in the desensitization of rhodopsin, a G protein-coupled receptor. Elife 2015, 4, e05981.
  7. Chen, J.; Makino, C.L.; Peachey, N.S.; Baylor, D.A.; Simon, M.I. Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant. Science 1995, 267, 374–377.
  8. Kuhn, H.; Hall, S.W.; Wilden, U. Light-induced binding of 48-kDa protein to photoreceptor membranes is highly enhanced by phosphorylation of rhodopsin. FEBS Lett. 1984, 176, 473–478.
  9. Wilden, U. Duration and amplitude of the light-induced cGMP hydrolysis in vertebrate photoreceptors are regulated by multiple phosphorylation of rhodopsin and by arrestin binding. Biochemistry 1995, 34, 1446–1454.
  10. Wilden, U.; Hall, S.W.; Kühn, H. Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. Proc. Natl. Acad. Sci. USA 1986, 83, 1174–1178.
  11. Gross, O.P.; Burns, M.E. Control of rhodopsin’s active lifetime by arrestin-1 expression in mammalian rods. J. Neurosci. 2010, 30, 3450–3457.
  12. Lohse, M.J.; Benovic, J.L.; Codina, J.; Caron, M.G.; Lefkowitz, R.J. beta-Arrestin: A protein that regulates beta-adrenergic receptor function. Science 1990, 248, 1547–1550.
  13. Lohse, M.J.; Andexinger, S.; Pitcher, J.; Trukawinski, S.; Codina, J.; Faure, J.P.; Caron, M.G.; Lefkowitz, R.J. Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. J. Biol. Chem. 1992, 267, 8558–8564.
  14. Attramadal, H.; Arriza, J.L.; Aoki, C.; Dawson, T.M.; Codina, J.; Kwatra, M.M.; Snyder, S.H.; Caron, M.G.; Lefkowitz, R.J. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J. Biol. Chem. 1992, 267, 17882–17890.
  15. Rapoport, B.; Kaufman, K.D.; Chazenbalk, G.D. Cloning of a member of the arrestin family from a human thyroid cDNA library. Mol. Cell. Endocrinol. 1992, 84, R39–R43.
  16. Sterne-Marr, R.; Gurevich, V.V.; Goldsmith, P.; Bodine, R.C.; Sanders, C.; Donoso, L.A.; Benovic, J.L. Polypeptide variants of beta-arrestin and arrestin3. J. Biol. Chem. 1993, 268, 15640–15648.
  17. Murakami, A.; Yajima, T.; Sakuma, H.; McLaren, M.J.; Inana, G. X-arrestin: A new retinal arrestin mapping to the X chromosome. FEBS Lett. 1993, 334, 203–209.
  18. Craft, C.M.; Whitmore, D.H.; Wiechmann, A.F. Cone arrestin identified by targeting expression of a functional family. J. Biol. Chem. 1994, 269, 4613–4619.
  19. Gurevich, V.V.; Gurevich, E.V. The structural basis of arrestin-mediated regulation of G protein-coupled receptors. Pharmacol. Ther. 2006, 110, 465–502.
  20. Peterson, Y.K.; Luttrell, L.M. The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling. Pharmacol. Rev. 2017, 69, 256–297.
  21. Xiao, K.; McClatchy, D.B.; Shukla, A.K.; Zhao, Y.; Chen, M.; Shenoy, S.K.; Yates, J.R.; Lefkowitz, R.J. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc. Natl. Acad. Sci. USA 2007, 104, 12011–12016.
  22. Gurevich, V.V.; Gurevich, E.V. Plethora of functions packed into 45 kDa arrestins: Biological implications and possible therapeutic strategies. Cell. Mol. Life Sci. 2019, 76, 4413–4421.
  23. Granzin, J.; Wilden, U.; Choe, H.W.; Labahn, J.; Krafft, B.; Buldt, G. X-ray crystal structure of arrestin from bovine rod outer segments. Nature 1998, 391, 918–921.
  24. Hirsch, J.A.; Schubert, C.; Gurevich, V.V.; Sigler, P.B. The 2.8 A crystal structure of visual arrestin: A model for arrestin’s regulation. Cell 1999, 97, 257–269.
  25. Sander, C.L.; Luu, J.; Kim, K.; Furkert, D.; Jang, K.; Reichenwallner, J.; Kang, M.; Lee, H.J.; Eger, B.T.; Choe, H.W.; et al. Structural evidence for visual arrestin priming via complexation of phosphoinositols. Structure 2022, 30, 263–277.
  26. Han, M.; Gurevich, V.V.; Vishnivetskiy, S.A.; Sigler, P.B.; Schubert, C. Crystal structure of beta-arrestin at 1.9 A: Possible mechanism of receptor binding and membrane translocation. Structure 2001, 9, 869–880.
  27. Milano, S.K.; Pace, H.C.; Kim, Y.M.; Brenner, C.; Benovic, J.L. Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. Biochemistry 2002, 41, 3321–3328.
  28. Zhan, X.; Gimenez, L.E.; Gurevich, V.V.; Spiller, B.W. Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual arrestins. J. Mol. Biol. 2011, 406, 467–478.
  29. Sutton, R.B.; Vishnivetskiy, S.A.; Robert, J.; Hanson, S.M.; Raman, D.; Knox, B.E.; Kono, M.; Navarro, J.; Gurevich, V.V. Crystal Structure of Cone Arrestin at 2.3 Å: Evolution of Receptor Specificity. J. Mol. Biol. 2005, 354, 1069–1080.
  30. Hanson, S.M.; Vishnivetskiy, S.A.; Hubbell, W.L.; Gurevich, V.V. Opposing effects of inositol hexakisphosphate on rod arrestin and arrestin2 self-association. Biochemistry 2008, 47, 1070–1075.
  31. Schubert, C.; Hirsch, J.A.; Gurevich, V.V.; Engelman, D.M.; Sigler, P.B.; Fleming, K.G. Visual arrestin activity may be regulated by self-association. J. Biol. Chem. 1999, 274, 21186–21190.
  32. Hanson, S.M.; Dawson, E.S.; Francis, D.J.; Van Eps, N.; Klug, C.S.; Hubbell, W.L.; Meiler, J.; Gurevich, V.V. A model for the solution structure of the rod arrestin tetramer. Structure 2008, 16, 924–934.
  33. Kim, M.; Hanson, S.M.; Vishnivetskiy, S.A.; Song, X.; Cleghorn, W.M.; Hubbell, W.L.; Gurevich, V.V. Robust self-association is a common feature of mammalian visual arrestin-1. Biochemistry 2011, 50, 2235–2242.
  34. Vishnivetskiy, S.A.; Chen, Q.; Palazzo, M.C.; Brooks, E.K.; Altenbach, C.; Iverson, T.M.; Hubbell, W.L.; Gurevich, V.V. Engineering visual arrestin-1 with special functional characteristics. J. Biol. Chem. 2013, 288, 3394–3405.
  35. Hanson, S.M.; Van Eps, N.; Francis, D.J.; Altenbach, C.; Vishnivetskiy, S.A.; Arshavsky, V.Y.; Klug, C.S.; Hubbell, W.L.; Gurevich, V.V. Structure and function of the visual arrestin oligomer. EMBO J. 2007, 26, 1726–1736.
  36. Song, X.; Vishnivetskiy, S.A.; Seo, J.; Chen, J.; Gurevich, E.V.; Gurevich, V.V. Arrestin-1 expression in rods: Balancing functional performance and photoreceptor health. Neuroscience 2011, 174, 37–49.
  37. Hanson, S.M.; Gurevich, E.V.; Vishnivetskiy, S.A.; Ahmed, M.R.; Song, X.; Gurevich, V.V. Each rhodopsin molecule binds its own arrestin. Proc. Natl. Acad. Sci. USA 2007, 104, 3125–3128.
  38. Strissel, K.J.; Sokolov, M.; Trieu, L.H.; Arshavsky, V.Y. Arrestin translocation is induced at a critical threshold of visual signaling and is superstoichiometric to bleached rhodopsin. J. Neurosci. 2006, 26, 1146–1153.
  39. Gurevich, E.V.; Benovic, J.L.; Gurevich, V.V. Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 2002, 109, 421–436.
  40. Gurevich, E.V.; Benovic, J.L.; Gurevich, V.V. Arrestin2 expression selectively increases during neural differentiation. J. Neurochem. 2004, 91, 1404–1416.
  41. Gurevich, V.V.; Hanson, S.M.; Song, X.; Vishnivetskiy, S.A.; Gurevich, E.V. The functional cycle of visual arrestins in photoreceptor cells. Prog. Retin. Eye Res. 2011, 30, 405–430.
  42. Fuchs, S.; Nakazawa, M.; Maw, M.; Tamai, M.; Oguchi, Y.; Gal, A. A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat. Genet. 1995, 10, 360–362.
  43. Yamamoto, S.; Sippel, K.C.; Berson, E.L.; Dryja, T.P. Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness. Nat. Genet. 1997, 15, 175–178.
  44. Chen, C.K.; Burns, M.E.; Spencer, M.; Niemi, G.A.; Chen, J.; Hurley, J.B.; Baylor, D.A.; Simon, M.I. Abnormal photoresponses and light-induced apoptosis in rods lacking rhodopsin kinase. Proc. Natl. Acad. Sci. USA 1999, 96, 3718–3722.
  45. Song, X.; Vishnivetskiy, S.A.; Gross, O.P.; Emelianoff, K.; Mendez, A.; Chen, J.; Gurevich, E.V.; Burns, M.E.; Gurevich, V.V. Enhanced Arrestin Facilitates Recovery and Protects Rod Photoreceptors Deficient in Rhodopsin Phosphorylation. Curr. Biol. 2009, 19, 700–705.
  46. Samaranayake, S.; Song, X.; Vishnivetskiy, S.A.; Chen, J.; Gurevich, E.V.; Gurevich, V.V. Enhanced Mutant Compensates for Defects in Rhodopsin Phosphorylation in the Presence of Endogenous Arrestin-1. Front. Mol. Neurosci. 2018, 11, 203.
  47. Song, X.; Seo, J.; Baameur, F.; Vishnivetskiy, S.A.; Chen, Q.; Kook, S.; Kim, M.; Brooks, E.K.; Altenbach, C.; Hong, Y.; et al. Rapid degeneration of rod photoreceptors expressing self-association-deficient arrestin-1 mutant. Cell. Signal. 2013, 25, 2613–2624.
  48. Moaven, H.; Koike, Y.; Jao, C.C.; Gurevich, V.V.; Langen, R.; Chen, J. Visual arrestin interaction with clathrin adaptor AP-2 regulates photoreceptor survival in the vertebrate retina. Proc. Natl. Acad. Sci. USA 2013, 110, 9463–9468.
  49. Samaranayake, S.; Vishnivetskiy, S.A.; Shores, C.R.; Thibeault, K.C.; Kook, S.; Chen, J.; Burns, M.E.; Gurevich, E.V.; Gurevich, V.V. Biological Role of Arrestin-1 Oligomerization. J. Neurosci. 2020, 40, 8055–8069.
  50. Nair, K.S.; Hanson, S.M.; Mendez, A.; Gurevich, E.V.; Kennedy, M.J.; Shestopalov, V.I.; Vishnivetskiy, S.A.; Chen, J.; Hurley, J.B.; Gurevich, V.V.; et al. Light-dependent redistribution of arrestin in vertebrate rods is an energy-independent process governed by protein-protein interactions. Neuron 2005, 46, 555–567.
  51. Slepak, V.Z.; Hurley, J.B. Mechanism of light-induced translocation of arrestin and transducin in photoreceptors: Interaction-restricted diffusion. IUBMB Life 2008, 60, 2–9.
  52. Eckmiller, M.S. Microtubules in a rod-specific cytoskeleton associated with outer segment incisures. Vis. Neurosci. 2000, 17, 711–722.
  53. Najafi, M.; Maza, N.A.; Calvert, P.D. Steric volume exclusion sets soluble protein concentrations in photoreceptor sensory cilia. Proc. Natl. Acad. Sci. USA 2012, 109, 203–208.
  54. Hanson, S.M.; Cleghorn, W.M.; Francis, D.J.; Vishnivetskiy, S.A.; Raman, D.; Song, X.; Nair, K.S.; Slepak, V.Z.; Klug, C.S.; Gurevich, V.V. Arrestin mobilizes signaling proteins to the cytoskeleton and redirects their activity. J. Mol. Biol. 2007, 368, 375–387.
  55. Storez, H.; Scott, M.G.; Issafras, H.; Burtey, A.; Benmerah, A.; Muntaner, O.; Piolot, T.; Tramier, M.; Coppey-Moisan, M.; Bouvier, M.; et al. Homo- and hetero-oligomerization of beta-arrestins in living cells. J. Biol. Chem. 2005, 280, 40210–40215.
  56. Milano, S.K.; Kim, Y.M.; Stefano, F.P.; Benovic, J.L.; Brenner, C. Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hexakisphosphate binding. J. Biol. Chem. 2006, 281, 9812–9823.
  57. Chen, Q.; Zhuo, Y.; Sharma, P.; Perez, I.; Francis, D.J.; Chakravarthy, S.; Vishnivetskiy, S.A.; Berndt, S.; Hanson, S.M.; Zhan, X.; et al. An Eight Amino Acid Segment Controls Oligomerization and Preferred Conformation of the two Non-visual Arrestins. J. Mol. Biol. 2021, 433, 166790.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biochemistry & Molecular Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Vsevolod V. Gurevich
,
Eugenia V. Gurevich
View Times: 404
Entry Collection: Biopharmaceuticals Technology
Revisions: 2 times (View History)
Update Date: 18 Jul 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback